Alector, Inc. (ALEC)

🇺🇸NASDAQ

5.73 +0.19 (3.43%)

At close: Jul 15, 2024, 4:00 PM

Market Cap552.3M
Days Range5.48 - 5.9
52 Week Range9.065 - 3.66
Volume498773
EPS (ttm)-1.39
PE Ratio-4.12

3.43% (1D)

Alector, Inc. News

news image

1 month ago - globenewswire.com

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation


news image

2 months ago - globenewswire.com

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:


news image

2 months ago - zacks.com

Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.55 per share a year ago.


news image

2 months ago - zacks.com

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.


news image

4 months ago - globenewswire.com

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:


news image

4 months ago - seekingalpha.com

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript


news image

4 months ago - globenewswire.com

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023


news image

4 months ago - globenewswire.com

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT


news image

4 months ago - zacks.com

Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.


news image

5 months ago - zacks.com

Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?

Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.


news image

5 months ago - globenewswire.com

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally


news image

5 months ago - globenewswire.com

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

-Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthrough Therapy Designation for the treatment of FTD-GRN-


news image

5 months ago - zacks.com

Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know

Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.


news image

5 months ago - investorplace.com

Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs

Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,” preventing some victims from walking.


news image

5 months ago - globenewswire.com

Alector Announces Closing of Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its underwritten public offering of shares of its common stock. Alector sold 10,869,566 shares of its common stock in the offering. Alector has granted the underwriter a 30-day option to purchase up to an additional 1,630,434 shares of its common stock. The gross proceeds to Alector from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $75 million.


news image

6 months ago - seekingalpha.com

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using AL101 for the treatment of patients with Alzheimer's Disease. The global market for Alzheimer's Disease is expected to reach $15.5 billion by 2031.


news image

6 months ago - globenewswire.com

Alector Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Alector. The offering is expected to close on January 19, 2024, subject to satisfaction of customary closing conditions. All of the shares in the offering are being sold by Alector.


news image

6 months ago - globenewswire.com

Alector Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In connection with the proposed offering, Alector expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of its common stock offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. All of the shares in the proposed offering are being sold by Alector.


news image

7 months ago - zacks.com

Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 142.5% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.


news image

7 months ago - marketbeat.com

These biotechs targeting multiple neurodegenerative diseases

Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive functions, motor functions, or sometimes both.


news image

7 months ago - globenewswire.com

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively


news image

8 months ago - zacks.com

Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Alector (ALEC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.


news image

8 months ago - globenewswire.com

Alector to Participate in the Stifel Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 11:30 a.m. ET.


news image

8 months ago - globenewswire.com

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants


news image

8 months ago - globenewswire.com

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has achieved target enrollment in INFRONT-3, the pivotal Phase 3 clinical trial of latozinemab (AL001). INFRONT-3 is evaluating the safety and efficacy of latozinemab in slowing disease progression in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). Latozinemab is an investigational human monoclonal antibody designed to block sortilin, a degradation receptor for progranulin (PGRN). It is intended to elevate PGRN levels and enhance the activity of microglia, the primary cells of the brain's innate immune system. Latozinemab is the most advanced PGRN modulating product candidate in clinical trials and the most advanced potential treatment for FTD-GRN. Latozinemab is being developed in collaboration with GSK.